Results 91 to 100 of about 72,180 (288)
Background. Anatomical variations of cystic duct (CD) are frequently unrecognized. It is important to be aware of these variations prior to any surgical, percutaneous, or endoscopic intervention procedures. Objectives.
Radha Sarawagi +3 more
semanticscholar +1 more source
When Enzymes Mislead: Assessing the Value of MRCP in Suspected Choledocholithiasis
ABSTRACT Background The diagnosis of choledocholithiasis (CDL) requires balancing timely intervention against the risks of unnecessary invasive procedures. Although liver function tests (LFTs) are widely used for risk stratification, their static values and short‐term trends remain poorly defined in predicting persistent common bile duct stones.
Renato Pitesa +4 more
wiley +1 more source
Evaluation of Clonidine Premedication on Hemodynamic Hyperactivity in Patients Candidate for ERCP
Background and Objectives Autonomic system changes during ERCP lead to increased blood pressure(BP) and heart rate (HR) and decrease in arterial O 2 saturation(SPO 2 ).
M Davoodi +3 more
doaj
Abstract Background Annual surveillance for cholangiocarcinoma using magnetic resonance cholangiopancreatography (MRCP) has been recommended in primary sclerosing cholangitis (PSC) to improve the associated dismal outcomes. However, data are limited. Aims To compare the outcomes of surveillance versus non‐surveillance in patients with PSC.
Gary Dezhi Zhang +11 more
wiley +1 more source
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad +10 more
wiley +1 more source
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [PDF]
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast ...
Chien, A Jo +5 more
core
Management of an Accessory Bile Duct Leak Following Pancreaticoduodenectomy: A Novel Approach Utilizing a Percutaneous and Endoscopic Rendezvous. [PDF]
Biliary leaks are uncommon but morbid complications of pancreaticoduodenectomies, which have historically been managed with percutaneous drainage, reoperation, or a combination of both. We report a de novo percutaneous-endoscopic hepaticojejunostomy from
Huang, Jason Y +4 more
core +1 more source
Artificial Intelligence Applications in Body MRI: Opportunities and Limitations
Journal of Magnetic Resonance Imaging, EarlyView.
Haresh Naringrekar, Abdullah Alturki
wiley +1 more source
Pancreatitis‐related gene variants are associated with a higher incidence of post‐ERCP hyperpancreatic enzymemia, whereas no significant association is observed with post‐ERCP pancreatitis. These findings suggest that genetic background contributes to early biochemical pancreatic injury after ERCP and may help identify patients with increased ...
Daishi Kabemura +16 more
wiley +1 more source
COMPARISON OF ULTRASOUND WITH ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY AND SURGERY IN THE DETECTION OF SITE AND CAUSE BILE DUCTS DILATATION [PDF]
background and Objectives: Ultrasound (US) is the initial imaging test used in the evaluation of patients with biliary tract disease. Our retrospective study was designed to evaluate the capacity of ultrasound to determine the cause and site of bile ...
تبرائی, یاسر +3 more
core

